Sustainability

Lawmakers should support the centralized progress made on ingredient evaluation, labeling, and packaging protections by specialized national children’s health agencies instead of allowing jurisdiction confusion that ultimately hinders healthcare advancement for all ages.

View members-only reports outlining progress on CHPA state legislative priorities.

CHPA opposes mandatory manufacturer-funded drug take-back programs as they threaten the affordability of OTC medications that consumers rely on as the first line of defense against common ailments.

CHPA encourages state and local lawmakers to refrain from creating new legislation addressing green chemistry in pharmaceuticals, and instead rely on the rigorous guidelines and standards already implemented at the federal level by agencies like the FDA.

Though rising PFAS levels prompt important health questions that must be monitored, restrictions should remain grounded in conclusive toxicology to avoid reactionary bans on safe modern alternatives — as inconsistent standards across 50 individual states would only stifle healthcare advancement.